Liquid Rice Grain OsrHSA For MRNA Vaccine Protectant

Recombinant human serum albumin liquid for mRNA vaccine protectant

Description

mRNA vaccine is one of nucleic acid vaccines and one currently researched most vaccine. The mechanism of mRNA vaccine is to deliver the mRNA encoding the antigen protein into the body through a delivery vector and express the target antigen protein to induce the body to produce an immune response and memory to prevent or treat diseases. mRNA vaccines are divided into non-replicating mRNA, replicating mRNA and in vitro dendritic cell non-replicating mRNA vaccines (dendritic cell(DC) are isolated from the patient’s blood, transfected with the target mRNA sequence, and then deliver to the body to induce the desired immune response ).

In order to prevent the transfected DC cells clumping together in the final mRNA vaccine products and after vaccinated into the body, a protective agent is essential to the mRNA vaccine as a final component. Albumin has been studied to be a good protective agent, which can prevent cells clumping together. Traditionally, it involves the use of human serum albumin(HSA). However, Using HSA has infection risk of pathogens such as AIDS, hepatitis B, prions via vaccination. In addition, vaccine manufacturers may suffer the risk of shortage of HSA supply due to blood source restrictions.

Recombinant human serum albumin(OsrHSA) can be an efficiency alternative. OsrHSA is derived from rice grains, can provide an excellent solution to utilise a safer, more defined and consistent material.

OsrHSA has a series of advantages, such as:

1. Animal or human component free, eliminate the risk of transmitting blood-origin pathogens via vaccination
2. High batch consistency, avoid interference of different batches of serum.
3. Chemical defined, without unknown ingredients, and will not induce undirected differentiation.
4. High capacity and stable supply: the production capacity of OsrHSA is one-metric ton.
5. Has gained the DMF from US FDA.
6. Without Surface active agent Tween 80.

Wuhan Healthgen Biotechnology Corp. (Healthgen Biotech), focusing on developing, manufacturing and marketing a series of plant derived pharmaceutical products, is a private company founded in 2006. Using the State-of-the-Art platform called OryzHiExp, Healthgen Biotech has high capacity to express proteins or small peptides in the rice grain and maximizes the innovative animal-free product development opportunities for clients and partners. Its cost-effective expression capability made it as a breakthrough expression platform. To date, Healthgen Biotech has obtained 41 invention patents related to recombinant protein expression and purification technology platforms and recombinant human serum albumin all over the world.